A
Harmony Biosciences Holdings, I — Earnings Quality Grade A
HRMY · Healthcare
Strong financial health
Revenue
$868M
2025
Net Income
$159M
2025
Gross Margin
77.2%
Free Cash Flow
$348M
01
Screening Summary
15
Passed
1
Watch
0
Failed
—
M-Score
管理层信号
最近 SEC 8-K 文件中未发现 CEO、CFO、董事会或审计负责人变动信号。
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
✓
A1DSO Change
DSO 41 days, change -2 days YoY
✓
A2AR vs Revenue Growth
AR growth 16.6% vs revenue growth 21.5%
✓
A3Revenue vs CFFO
Revenue 21.5%, CFFO 58.4%. Cash follows revenue
02
Expense Quality
✓
B1Inventory vs COGS
Inventory -25.6% vs COGS 26.5%. Normal
✓
B2CapEx vs Revenue
CapEx growth -73.1% vs revenue 21.5%. Normal
✓
B3SG&A Ratio
SG&A/Gross Profit = 40.6%. Normal
✓
B4Gross Margin
Gross margin 77.2%, change -0.9pp. Stable
03
Cash Flow Quality
✓
C1CFFO vs Net Income
CFFO/NI = 2.19. Profits backed by cash
✓
C2Free Cash Flow
FCF $0.3B, FCF/NI = 2.19
✓
C3Accruals Ratio
Accruals ratio = -14.9%. Low accruals
✓
C4Cash vs Debt
Cash $0.8B covers debt $0.2B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
No goodwill. Clean balance sheet
✓
D2Leverage
Debt/EBITDA = 0.6x. Healthy
!
D3Soft Asset Growth
Other assets grew 147.8% vs revenue 21.5%
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
✓
E1Serial Acquirer FCF
FCF after acquisitions positive
✓
E2Goodwill Surge
No goodwill
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
7.28
Safe Zone0 Distress1.102.605.0+ Safe
0.515
Liquidity
0.1265
Cumulative profit
0.1806
Operating efficiency
2.1679
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25